News

Article

Efficacy of novel eye drop to reverse cataracts after phase 1/2 study

Author(s):

The drop improves vision by breaking up degraded protein complexes that cause lens clouding

(Image Credit: AdobeStock/IndiaPix)

(Image Credit: AdobeStock/IndiaPix)

Randall Olson, MD, corresponding author of the study, Moran Eye Center CEO and Distinguished Professor and Chair of the Department of Ophthalmology and Visual Sciences at the University of Utah, Salt Lake City, and colleagues reported that a novel eye drop (C-KAD, Livionex Inc.) has been formulated to treat early to moderate age-related cataracts. The drop improves vision by breaking up degraded protein complexes that cause lens clouding, which leads to cataracts and vision loss, when instilled in the eye.

They reported the results of their subgroup analysis in the American Journal of Ophthalmology.1

In a company press release, Olson said, “This therapy marks a crucial milestone in the field of ophthalmology. Currently, there are no FDA-approved pharmacological therapies for age-related cataract. Cataract surgery remains the only safe and effective treatment option available.”

Subgroup analysis

A randomized, double-blinded, placebo-controlled, multicentre Phase 1/2 clinical trial was conducted at six sites in the US and included 111 patients. A sub-analysis evaluated the efficacy of a topical 2.6% edetate disodium (EDTA) ophthalmic solution to improve vision in a subgroup of patients with decreased contrast sensitivity, the authors explained.

Subsequently, 41 eyes with reduced contrast sensitivity were included in the subgroup analysis; 21 patients received active treatment and 20 received placebo. The primary endpoint of the 4-month study was the proportion of patients with clinically significant improvements in contrast sensitivity.

The authors reported that C-KAD met the primary endpoint in 66.7% of eyes in contrast to 35% of eyes in the placebo group after 4 months. No serious adverse events were reported.

The authors also reported positive trends in the best-corrected visual acuity and improved lens transparency.

The investigators concluded, “A significant treatment effect of C-KAD in visual function and vision quality was observed consistently. These promising results suggest a novel, non-invasive pharmacological treatment to improve vision in patients with early-stage cataract.

They also believe that larger prospective clinical studies are warranted to confirm the results.

Reference:
  1. Kuboi T, Chuck RS, Pineda R II, et al. Subgroup analysis from a phase1/2 randomized clinicaltrial of 2.6% EDTA ophthalmic solution in patients with age-related cataract. Am J Ophthalmol. 2024; available online Aug 2. https://doi.org/10.1016/j.ajo.2024.07.038
Related Videos
Dr. Amir Ghanipour discusses light adjustable lenses for cataracts at EyeCon 2024
Arun Gulani, MD: How the Gni instrument enhances precision and control in cataract surgery
David Eichenbaum, MD, presents advances in AMD therapy, highlights different mechanisms with a common goal
Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.